Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.
Inclusion Criteria:
Participants must:
Exclusion Criteria
Participants must not:
CABA, Buenos Aires C1056ABJ, Argentina
CABA, Buenos Aires C1128AAF, Argentina
Caba, Buenos Aires C1179AAB, Argentina
Caba, Buenos Aires C1425DES, Argentina
CABA, Buenos Aires C1440CFD, Argentina
Ciudad Autonoma de Buenos Aire, Buenos Aires C1425AGC, Argentina
Ciudad Autonoma de, Buenos Aires C1119ACN, Argentina
Ciudad Autonoma de Buenos Aire, C1120AAC, Argentina
Ciudad Autonoma de Buenos Aire, C1204AAD, Argentina
Ciudad Autonoma de Buenos Aire, C1205AAO, Argentina
Rio de Janeiro, Rio de Janeiro 22271-100, Brazil
Merida, State of Mexico 97217, Mexico
Warsaw, Masovian Voivodeship 02-507, Poland
Rio Pedras, PR 00936, Puerto Rico
Taichung County, 433, Taiwan